Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs

Cancer Letters

Volumn 335, Issue 1, 2013, Pages 225-231

  Fabbri, Francesco ^a   Carloni, Silvia ^a   Zoli, Wainer ^a   Ulivi, Paola ^a   Gallerani, Giulia ^b   Fici, Pietro ^c   Chiadini, Elisa ^a   Passardi, Alessandro ^a   Frassineti, Giovanni L ^a   Ragazzini, Angela ^a   Amadori, Dino ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Colorectal cancer; CTCs; Dielectrophoresis; Heterogeneity; KRAS

Indexed keywords

ADULT; AGED; ARTICLE; CELL SELECTION; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; COLON CANCER; CONTROLLED STUDY; ELECTROPHORESIS; FEASIBILITY STUDY; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENETIC SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; KRAS GENE; LABORATORY DEVICE; LYMPHOCYTE; MALE; METASTASIS; PRIMARY TUMOR; PRIORITY JOURNAL;

AGED; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CELL SEPARATION; CENTRIFUGATION, DENSITY GRADIENT; COLONIC NEOPLASMS; ELECTROPHORESIS; FEMALE; HUMANS; KERATINS; MALE; MIDDLE AGED; MUTATION, MISSENSE; NEOPLASTIC CELLS, CIRCULATING; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA;

EID: 84878453265     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.02.015     Document Type: Article

References (33)

1. Attard G., de Bono J.S. Utilizing circulating tumor cells: challenges and pitfalls. Curr. Opin. Genet. Dev. 2011, 21:50-58.
2. Sun Y.F., Yang X.R., Zhou J., Qiu S.J., Fan J., Xu Y. Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance. J. Cancer. Res. Clin. Oncol. 2011, 137:1151-1173.
3. Pantel K., Alix-Panabières C. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol. Med. 2010, 16:398-406.
4. Maheswaran S., Haber D.A. Circulating tumor cells: a window into cancer biology and metastasis. Curr. Opin. Genet. Dev. 2010, 20:96-99.
5. Pantel K., Brakenhoff R.H., Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat. Rev. Cancer 2008, 8:329-340.
6. Bednarz-Knoll N., Alix-Panabières C., Pantel K. Clinical relevance and biology of circulating tumor cells. Breast Cancer Res. 2011, 13:228.
7. Allen J.E., El-Deiry W.S. Circulating tumor cells and colorectal cancer. Curr. Colorectal Cancer Rep. 2010, 6:212-220.
8. Negin B.P., Cohen S.J. Circulating tumor cells in colorectal cancer: past, present, and future challenges. Curr. Treat. Options Oncol. 2010, 11:1-13.
9. Van Cutsem E., Köhne C.H., Hitre E., Zaluski J., Chang Chien C.R., Makhson A., D'Haens G., Pintér T., Lim R., Bodoky G., Roh J.K., Folprecht G., Ruff P., Stroh C., Tejpar S., Schlichting M., Nippgen J., Rougier P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. New. Engl. J. Med. 2009, 360:1408-1417.
10. Cohen S.J., Punt C.J., Iannotti N., Saidman B.H., Sabbath K.D., Gabrail N.Y., Picus J., Morse M., Mitchell E., Miller M.C., Doyle G.V., Tissing H., Terstappen L.W., Meropol N.J. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008, 26:3213-3221.
11. Cohen S.J., Punt C.J., Iannotti N., Saidman B.H., Sabbath K.D., Gabrail N.Y., Picus J., Morse M., Mitchell E., Miller M.C., Doyle G.V., Tissing H., Terstappen L.W., Meropol N.J. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann. Oncol. 2009, 20:1223-1229.
12. Cohen S.J., Alpaugh R.K., Gross S., O'Hara S.M., Smirnov D.A., Terstappen L.W., Allard W.J., Bilbee M., Cheng J.D., Hoffman J.P., Lewis N.L., Pellegrino A., Rogatko A., Sigurdson E., Wang H., Watson J.C., Weiner L.M., Meropol N.J. Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin. Colorectal Cancer 2006, 6:125-132.
13. Rosenberg R., Gertler R., Friederichs J., Fuehrer K., Dahm M., Phelps R., Thorban S., Nekarda H., Siewert J.R. Comparison of two density gradient centrifugation systems for the enrichment of disseminated tumor cells in blood. Cytometry 2002, 49:150-158.
14. Balic M., Dandachi N., Hofmann G., Samonigg H., Loibner H., Obwaller A., van der Kooi A., Tibbe A.G., Doyle G.V., Terstappen L.W., Bauernhofer T. Comparison of two methods for enumerating circulating tumor cells in carcinoma patients. Cytom. B Clin. Cytom. 2005, 68:25-30.
15. Königsberg R., Gneist M., Jahn-Kuch D., Pfeiler G., Hager G., Hudec M., Dittrich C., Zeillinger R. Circulating tumor cells in metastatic colorectal cancer: efficacy and feasibility of different enrichment methods. Cancer Lett. 2010, 293:117-123.
16. Gasch C., Bauernhofer T., Pichler M., Langer-Freitag S., Reeh M., Seifert A.M., Mauermann O., Izbicki J.R., Pantel K., Riethdorf S. Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. Clin. Chem. 2013, 59(1):252-260.
17. Sastrea J., Luisa Maestrob M., Gómez-Españac A., Riverad F., Valladarese M., Massutif B., Benavidesg M., Gallénh M., Marcuelloi E., Abadj A., Arrivik A., Fernández-Martosl C., Gonzálezm E, Taberneron J.M., Vidaurretab M., Arandac E., Díaz-Rubioa E. Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a spanish cooperative group for the treatment of digestive tumors study. Oncologist 2012, 17:947-955.
18. B. Mostert, Y. Jiang, A.M. Sieuwerts, H. Wang, J. Bolt-de Vries, K. Biermann, J. Kraan, Z. Lalmahomed, A. Galen, V. de Weerd, P. van der Spoel, R. Ramírez-Moreno, C. Verhoef, J.N.M. IJzermans, Y. Wang, J. Gratama, J.A. Foekens, S. Sleijfer, J.W.M. Martens, KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue, Int. J. Cancer, in press. doi:10.1002/ijc.27987.
19. Swaby R.F., Cristofanilli M. Circulating tumor cells in breast cancer: a tool whose time has come of age. BMC Med. 2011, 9.
20. Pestrin M., Bessi S., Galardi F., Truglia M., Biggeri A., Biagioni C., Cappadona S., Biganzoli L., Giannini A., Di Leo A. Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res. Treat. 2009, 118:523-530.
21. Fehm T., Müller V., Aktas B., Janni W., Schneeweiss A., Stickeler E., Lattrich C., Löhberg C.R., Solomayer E., Rack B., Riethdorf S., Klein C., Schindlbeck C., Brocker K., Kasimir-Bauer S., Wallwiener D., Pantel K. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res. Treat. 2010, 124:403-412.
22. Hayashi N., Nakamura S., Tokuda Y., Shimoda Y., Yagata H., Yoshida A., Ota H., Hortobagyi G.N., Cristofanilli M., Ueno N.T. Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer. Int. J. Clin. Oncol. 2012, 17:96-104.
23. Marusyk A., Almendro V., Polyak K. Intra-tumour heterogeneity: a looking glass for cancer?. Nat. Rev. Cancer 2012, 12:323-334.
24. Stoecklein N.H., Klein C.A. Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis. Int. J. Cancer 2010, 126:589-598.
25. Klein C.A. Parallel progression of primary tumours and metastases. Nat. Rev. Cancer 2009, 9:302-312.
26. Pantel K., Denève E., Nocca D., Coffy A., Vendrell J.P., Maudelonde T., Riethdorf S., Alix-Panabières C. Circulating epithelial cells in patients with benign colon diseases. Clin. Chem. 2012, 58:936-940.
27. Medina A., Brown E., Carr N., Ghahary A. Circulating monocytes have the capacity to be transdifferentiated into keratinocyte-like cells. Wound Repair Regen. 2009, 17:268-277.
28. Italiano A., Hostein I., Soubeyran I., Fabas T., Benchimol D., Evrard S., Gugenheim J., Becouarn Y., Brunet R., Fonck M., François E., Saint-Paul M.C., Pedeutour F. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. Ann. Surg. Oncol. 2010, 17:1429-1434.
29. Mariani P., Lae M., Degeorges A., Cacheux W., Lappartient E., Margogne A., Pierga J.Y., Girre V., Mignot L., Falcou M.C., Salmon R.J., Delattre O., De Cremoux P. Concordant analysis of KRAS status in primary colon carcinoma and matched metastasis. Anticancer Res. 2010, 30:4229-4235.
30. Watanabe T., Kobunai T., Yamamoto Y., Matsuda K., Ishihara S., Nozawa K., Iinuma H., Shibuya H., Eshima K. Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer. Dis. Colon Rectum 2011, 54:1170-1178.
31. Baas J.M., Krens L.L., Guchelaar H.J., Morreau H., Gelderblom H. Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review. Oncologist 2011, 16:1239-1249.
32. Li Z., Jin K., Lan H., Teng L. Heterogeneity in primary colorectal cancer and its corresponding metastases: a potential reason of EGFR-targeted therapy failure?. Hepatogastroenterology 2011, 58:411-416.
33. Oltedal S., Aasprong O.G., Møller J.H., Kørner H., Gilje B., Tjensvoll K., Birkemeyer E.M., Heikkilä R., Smaaland R., Nordgård O. Heterogeneous distribution of KRAS mutations in primary colon carcinomas: implications for EGFR-directed therapy. Int. J. Colorectal Dis. 2011, 26:1271-1277.